Clinical trials
Muscular Atrophy clinical trials
Below are recruiting muscular atrophy clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07400198Recruiting
Walking and Bone Health Study for SMA
This study looks at walking and bone health in people with spinal muscular atrophy (SMA). It helps researchers understand how SMA affects your gait (the way you walk) and your bones, which could lead to better treatments.
New York, New YorkAges 8–50 - NCT05824169RecruitingPhase 1/Phase 2
Gene therapy for babies with severe spinal muscular atrophy
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
BeijingAges birth–6 months - NCT06421831RecruitingPhase 1/Phase 2
Gene therapy trial for spinal muscular atrophy type 3
This trial is testing a one-time gene therapy drug for people with SMA type 3. The goal is to see if it can safely improve muscle function and strength.
Beijing, Beijing MunicipalityAges 2 years+ - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT06321965Recruiting
Study of SMA in Children on SMN-Boosting Therapies
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Bron, RhoneAges birth–16 years - NCT06532474Recruiting
Muscle function study in SMA patients on SMN therapies
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
Memphis, TennesseeAges 5–20 - NCT07223489Recruiting
Understanding Adult SMA Diagnosis & Treatment Experiences
This trial explores the experiences of adults with spinal muscular atrophy (SMA) in the MedStar Health System, looking at how they are diagnosed and treated, and any differences in care they may face.
Washinton, District of ColumbiaAges 18 years+ - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT07444450RecruitingPhase 3
Study of salanersen for babies with SMA previously treated with gene therapy
This study tests a new medicine called salanersen in babies who have already received gene therapy for SMA. It aims to see if adding salanersen is safe and effective.
Flower Mound, TexasAges birth–7 months - NCT06147414Recruiting
Blood test for genetic disorders in pregnancy
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
ParisAges 18 years+ - NCT07265232RecruitingPhase 3
Gene therapy for spinal muscular atrophy in low-resource settings
This trial tests a new gene therapy called Vesemnogene Lantuparvovec for people with spinal muscular atrophy (SMA). It is designed for patients in low- and middle-income countries who cannot access or did not respond to other treatments. The goal is to see if the therapy is safe and effective in real-world conditions.
Jakarta, IndonesiaAges 6 months+ - NCT07543003Recruiting
Wearable Monitoring for Young Children With Spinal Muscular Atrophy
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
OxfordAges Up to 4 years - NCT05861999RecruitingPhase 4
Risdiplam for young children with SMA after gene therapy plateau
This trial studies whether risdiplam is safe and helpful for children under 2 with spinal muscular atrophy (SMA) whose function has leveled off or declined after gene therapy. It may be an option if you saw benefits from gene therapy but then noticed a stop or setback in key abilities.
Little Rock, ArkansasAges 3 months–2 years - NCT07467187Recruiting
Home Ventilation with Tracheostomy in Denmark (2016–2025)
This study looks at people in Denmark who need a home ventilator through a tracheostomy. It aims to understand their care and outcomes over several years.
CopenhagenAges Any age - NCT05789758Recruiting
Study of Spinraza in pregnancy for 5q spinal muscular atrophy
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
Palo Alto, CaliforniaAges 18–54 - NCT07444476RecruitingPhase 3
Study of salanersen for spinal muscular atrophy (ages 15-60)
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
Norfolk, VirginiaAges 15–60 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT07521930Recruiting
Brain implant to restore communication and movement control
This trial tests a surgically implanted brain device designed to help people with severe paralysis or movement disorders regain the ability to communicate and control their limbs. The device reads signals from your brain and translates them into commands that could help you interact with computers or assistive technology.
Baltimore, MarylandAges 18–80 - NCT06363357Recruiting
Shoulder brace study for arm weakness from nerve or muscle diseases
This study tests a fabric shoulder brace that moves like a muscle. It may help people with nerve or muscle diseases improve arm movements like reaching and lifting.
Seoul, Jongno-guAges 10 years+ - NCT06756633Recruiting
Breathing and movement study for neuromuscular disease
This study looks at breathing, chest and belly movement, and exercise ability in people with Duchenne Muscular Dystrophy or Spinal Muscular Atrophy, as well as healthy people. The goal is to compare these functions to help understand how these diseases affect the body.
Ankara, ÇankayaAges 5–15 - NCT06839469Recruiting
Walking study for rare muscle and nerve conditions
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
Palo Alto, CaliforniaAges 5 years+ - NCT06940284Recruiting
Food intake and health in hospitalized elderly
This study looks at how much food older adults eat while in the hospital and whether that affects their muscles and recovery. It may help understand the role nutrition plays in staying strong during a hospital stay.
São Paulo, São PauloAges 65 years+ - NCT06666816Recruiting
Watching changes in walking for muscle and nerve diseases
This study watches how people with certain muscle or nerve diseases walk over time. It may help doctors understand changes in walking patterns and is open to adults who can walk and have a genetic diagnosis of a neuromuscular condition.
Bosisio Parini, LeccoAges 18–75 - NCT07321977Recruiting
Walking test with a portable device for neuromuscular disease
This study tests a portable device that analyzes walking without markers. It aims to see if it can help assess walking in people with neuromuscular diseases and healthy volunteers, which could lead to simpler check-ups.
ParisAges 18–65
Hear when a new Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscular atrophy?
- Yes. Clin2 currently lists 71 recruiting muscular atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscular atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscular atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.